In vitro activities of erythromycin A, telithromycin, and two investigational ketolides, JNJ-17155437 and JNJ-17155528, were evaluated against clinical bacterial strains, including selected common respiratory tract pathogens. Against 46 macrolide-susceptible and -resistant Streptococcus pneumoniae strains, the MIC 90 (MIC at which 90% of the isolates tested were inhibited) of the investigational ketolides was 0.25 g/ml, twofold lower than that of telithromycin and at least 64-fold lower than that of erythromycin A. Against erm(B)-containing pneumococci, the MIC 90 of all the ketolides was 0.06 g/ml. The MIC 90 of the investigational ketolides against mef(A)-containing pneumococci or pneumococci with both mef(A) and erm(B) was 0.25 g/ml, two-and fourfold lower, respectively, than that of telithromycin. In contrast, the MICs of the investigational ketolides against macrolide-resistant S. pneumoniae strains with ribosomal mutations were similar to or, in some cases, as much as eightfold higher than those of telithromycin. Against Haemophilus influenzae, MICs of all the ketolides were <2 g/ml. Against three Moraxella catarrhalis isolates, the MIC of the ketolides was 0.25 g/ml. The ketolides inhibited in vitro protein synthesis, with 50% inhibitory concentrations ranging from 0.23 to 0.27 M. In time-kill studies against macrolide-susceptible and erm-or mef-containing pneumococci, the ketolides were bacteriostatic to slowly bactericidal, with 24-h log 10 decreases ranging from 2.0 to 4.1 CFU. Intervals of postantibiotic effects for the ketolides against macrolide-susceptible and -resistant S. pneumoniae were 3.0 to 8.1 h.Respiratory tract infections, including community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS), and pharyngitis, are a frequent cause of illness and, for CAP, a substantial cause of mortality (3,22). Streptococcus pneumoniae and Haemophilus influenzae are responsible for a majority of the cases of CAP, AECB, and ABS, while Streptococcus pyogenes is the primary causal agent for pharyngitis (5, 23). Macrolides efficacious against S. pneumoniae and H. influenzae are first-line agents for the treatment of CAP (10,16,28) and are second-line agents for the treatment of AECB (1). With ABS (2, 26) and pharyngitis (5, 25), macrolides are an important treatment option where intolerance to penicillins is a concern.Macrolide resistance in pneumococci has been increasing since the early 1980s, with worldwide resistance levels of clinical isolates currently at approximately 25% in some studies (19,34). In the United States, macrolide nonsusceptibility varies by region from 17 to 36% (34), while nonsusceptibility outside the United States ranges from 1.5% in the Czech Republic to 80% in Hong Kong (19). Clinical macrolide resistance results primarily from the expression of the erm(B) dimethylase or the mef(A) efflux gene. The proportion of macrolide-resistant strains expressing the erm or mef phenotypes differs by region and by country. In the United Sta...